Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

Eli Lilly & Co. (LLY) shares have come under significant pressure in late May following a pivotal decision by CVS Health's ...

Novo Nordisk's Q1 showed robust sales/EPS growth, fueled by soaring GLP-1 demand in a multi-billion dollar market. Read why I ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

CVS Caremark identified GLP-1 drugs and Humira as points of contention, but the State Health Plan says that mischaracterizes ...

Health insurance plans are changing how they cover GLP-1 drugs for weight loss to rein in costs, forcing doctors and patients ...

Health-care companies rose amid sales growth optimism. Drug-store chain CVS Health said it has seen complaints of strong push back from patients on its pharmacy-benefit manager's move to favor Novo ...

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy ...

In an effort to promote the use of genuine products, Novo Nordisk is offering a one-time first-month offer for Wegovy at $199 ...

Novo Nordisk's early lead in weight-loss drugs fades as Eli Lilly surges ahead with more effective therapies and faster ...

Innovative access initiatives: A new partnership with Novo Nordisk will increase access to Wegovy, a GLP-1 weight loss drug, through CVS’s pharmacy network and Caremark benefit manager.

Novo also benefited recently from a CVS Health decision to make Wegovy the preferred option on its standard formulary, or list of covered drugs. CVS Health runs prescription drug coverage for ...